Day One Biopharmaceuticals Deal History & Licensing Activity
Day One Biopharmaceuticals is a large biotech headquartered in US. Over the past three years, Day One Biopharmaceuticals has been involved in 3 licensing and acquisition transactions, with a primary focus on ADC (4 deals). The company currently has 5 active clinical trials, primarily in Oncology.
Deals (12mo)
2
Active Trials
5
Top Modality
ADC
Focus Area
Oncology
Day One Biopharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Day One Biopharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Mersana ADC pipeline | Mersana Therapeutics | ADC | Unknown | acquisition | Jun 2, 2026 |
| Mersana Therapeutics (corporate acquisition) | Mersana Therapeutics | ADC | Unknown | acquisition | May 15, 2026 |
| Tovorafenib (DAY101) | Servier | Small Molecules | Unknown |
Day One Biopharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Day One Biopharmaceuticals is most active based on deal history and clinical trial data.
Day One Biopharmaceuticals Strategic Signals
Key indicators of Day One Biopharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Day One Biopharmaceuticals Clinical Pipeline
Day One Biopharmaceuticals has 5 active clinical trials across 3 development phases.
1
Phase 1
3
Phase 2
1
Phase 3
See How Your Asset Matches Day One Biopharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Day One Biopharmaceuticals Licensing & Deal Activity
Day One Biopharmaceuticals is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Day One Biopharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Day One Biopharmaceuticals include Oncology (4 deals and trials), Mega Deals (2 deals and trials), CNS Disorders (2 deals and trials), and Solid Tumors (1 deal and trial). In terms of modality, Day One Biopharmaceuticals has shown particular interest in adc, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Day One Biopharmaceuticals and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Day One Biopharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.